Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

AstraZeneca

Eccogene files for Hong Kong IPO

Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO

The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
October 23, 2025
HBM notches up another mega deal

HBM notches up another mega deal but is the model sustainable?

The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
July 3, 2025
2142.HK
TYK Medicines

A blockbuster cancer drug? TYK’s claims go under the microscope

The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
March 20, 2025
2410.HK
Earnings blow for CSPC Pharma

Earnings blow for CSPC Pharma as the state drives a hard bargain

The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines   Key Takeaways: CSPC Pharma…
March 6, 2025
1093.HK
AstraZnenca tax probe

AstraZeneca could face limited fallout from Chinese tax probe

The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
February 13, 2025
AZN.US
Illustration of McDonald's Big Mac

A McDonald’s Valuation Downsize, and New Medical Plan Additions

The value of McDonald's China operation has plunged by more than half in the last year.  And 91 companies got their drugs added to China's national health plan By Doug…
December 3, 2024

NEWS WRAP: AstraZeneca China president assisting in investigation

The British drugmaker said Leon Wang is currently cooperating with an ongoing probe, as media reported the case involved the defrauding of China’s national insurance fund   By A. Au…
November 4, 2024
AZN.US
Load more

Recent Articles

Eccogene files for Hong Kong IPO
October 23, 2025

Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO

July 3, 2025

HBM notches up another mega deal but is the model sustainable?

2142.HK
March 20, 2025

A blockbuster cancer drug? TYK’s claims go under the microscope

2410.HK
March 6, 2025

Earnings blow for CSPC Pharma as the state drives a hard bargain

1093.HK
February 13, 2025

AstraZeneca could face limited fallout from Chinese tax probe

AZN.US
December 3, 2024

A McDonald’s Valuation Downsize, and New Medical Plan Additions

November 4, 2024

NEWS WRAP: AstraZeneca China president assisting in investigation

AZN.US

RELATED ARTICLES

  1. Hengrui Pharma targets obesity drug launch
    July 24, 2025
    Hengrui Pharma targets obesity drug launch after test success
    1278.HK 600276.SHG
  2. October 9, 2025
    Obesity drug maker Sciwind targets IPO, with heavyweight backers
  3. July 3, 2025
    HBM notches up another mega deal but is the model sustainable?
    2142.HK
  4. June 26, 2025
    ​​Medtide launches IPO to bulk up its weight-loss business
    3880.HK
  5. May 29, 2025
    3SBio hits the big time with $6 billion cancer drug deal
    1530.HK
  6. October 16, 2025
    InnoCare licensing deal flops due to lack of upfront cash
    9969.HK 688428.SHG
  7. May 15, 2025
    Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
    9939.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.